Trovagene to Present at 25th Annual Piper Jaffray Conference

         Trovagene to Present at 25th Annual Piper Jaffray Conference

PR Newswire

SAN DIEGO, Dec. 2, 2013

SAN DIEGO, Dec. 2, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ:TROV), a
developer of cell-free molecular diagnostics, today announced that Chief
Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate
overview at the Piper Jaffray 25^th Annual Healthcare Conference.


Trovagene is scheduled to present at the Piper Jaffray 25th Annual Healthcare
Conference at the Palace Hotel in New York, NY on Wednesday, December 4, 2013
at 3:30 p.m. Mr. Schuh will be available for one-on-one meetings during the
conference. The presentation will be webcast live at and can also be accessed through the
investor relations page at A replay of the presentation
will be available at and will be archived for 90 days.

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is leveraging its patented
technology for the detection of cell-free DNA and RNA, short nucleic acid
fragments, originating from normal and diseased cell death that can be
isolated and detected from urine. Trovagene has a strong intellectual property
asset as it relates to cell-free DNA and RNA testing in urine. It has U.S. and
European patent applications and issued patents that cover testing for HPV and
other infectious diseases, cancer, transplantation, prenatal and genetic

Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimated" and "intend," among others.
These forward-looking statements are based on Trovagene's current expectations
and actual results could differ materially. There are a number of factors that
could cause actual events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not limited to,
substantial competition; our ability to continue as a going concern; our need
for additional financing; uncertainties of patent protection and litigation;
uncertainties of government or fourth party payer reimbursement; limited sales
and marketing efforts and dependence upon fourth parties; and risks related to
failure to obtain FDA clearances or approvals and noncompliance with FDA
regulations. As with any medical diagnostic tests under development, there are
significant risks in the development, regulatory approval and
commercialization of new products. There are no guarantees that future
clinical trials discussed in this press release will be completed or
successful or that any product will receive regulatory approval for any
indication or prove to be commercially successful. Trovagene does not
undertake an obligation to update or revise any forward-looking statement.
Investors should read the risk factors set forth in Trovagene's Form 10-K for
the year ended December 31, 2012 and other periodic reports filed with the
Securities and Exchange Commission.

Trovagene, Inc.
Financial                Investor Relations
Stephen Zaniboni         Amy Caterina

Chief Financial Officer  Investor Relations
Trovagene, Inc.          Trovagene, Inc.
858-952-7594             858-952-7593

SOURCE Trovagene, Inc.

Press spacebar to pause and continue. Press esc to stop.